Aptus Pharma Ltd H1 FY26 – ₹14.38 Cr Half-Year Sales, ₹1.75 Cr PAT, 71% ROE & a Geography So Concentrated Even Google Maps Is Bored
1. At a Glance – Blink and You’ll Miss the Volatility
Aptus Pharma Ltd is that classic Indian SME story where numbers look exciting, the stock chart looks like it drank three energy drinks, and the business model says, “Relax bro, we don’t even own a factory.” With a market cap of ₹117 Cr, a current price of ₹170, and a 103% return in just three months, Aptus has suddenly become that stock your WhatsApp group discovered after the rally. The latest half-year results (Sep 2025) show sales of ₹14.38 Cr and PAT of ₹1.75 Cr, translating into an OPM of ~20.4%—quite spicy for a pharma marketer. ROE is sitting at a jaw-dropping ~71%, which looks illegal until you realize the equity base just expanded post-IPO. Debt stands at ₹8.13 Cr, manageable but not pocket change. Stock P/E is hovering around 33x, slightly above industry median, which means expectations are already wearing a sherwani. This is not a sleepy distributor anymore; this is a stock that entered the wedding hall dancing. But is the music sustainable, or is the DJ about to unplug the AUX cable?
2. Introduction – Welcome to the Asset-Light, Geography-Heavy Circus
Aptus Pharma was incorporated in 2010 and spent most of its life quietly doing what thousands of Indian pharma marketers do—selling branded generics to doctors, chemists, and hospitals without owning a single manufacturing plant. No chimneys, no reactors, no FDA raids at midnight. Just marketing, distribution, and relationships. Very Indian. Very jugaad.
But 2025 changed the mood. The company went public, raised ₹12.3 Cr via IPO, cleaned up the balance sheet optics, and suddenly found itself under the harsh lighting of public markets. And what do public markets love? Growth charts and margin expansion. Aptus delivered both—at least on paper.
The catch? 99.2% of revenue comes from Gujarat. That’s not diversification; that’s a loyal long-distance relationship with one state. If Gujarat sneezes, Aptus catches cold. The company knows this, which is why management is talking about entering five new states and starting exports to emerging markets. Ambition is good. Execution is where SMEs either graduate or evaporate.
So the big question: is Aptus a disciplined marketer scaling responsibly, or just another regional pharma brand riding a temporary margin spike?
3. Business Model – WTF Do They Even Do?
Aptus Pharma is a pure-play pharma marketing and distribution company. Translation for lazy investors: they don’t manufacture medicines; they sell them. The actual pills, syrups, injections, and ointments are made by seven contract manufacturers located across Gujarat, Uttarakhand, and Himachal Pradesh. Two of these relationships are under formal loan/license agreements, while others are simple purchase-order based arrangements. No capex-heavy plants. No machinery depreciation headaches. Just branding, sales, and logistics.
The company boasts a portfolio of 194 finished formulations across 11+ therapeutic segments. That’s a lot of SKUs for a company with ₹24.56 Cr annual sales. On average, each product probably sells just enough to stay relevant. The portfolio spans tablets, capsules, softgels, syrups, injections, ointments, drops, gels, powders—you name it, they’ve probably labeled it.
The sales engine runs through 125 distributors and a field force of 54 medical representatives, supported by warehouses totaling roughly 17,700 sq. ft. in Ahmedabad. This is old-school Indian pharma marketing: doctor visits, chemist relationships, prescription generation, repeat orders.
It’s not glamorous, but it works—until competition intensifies or doctor loyalty shifts. The moat here is not technology; it’s relationships and reach. And those are fragile if incentives dry up. Would you trust your entire business on doctor goodwill alone?
4. Financials Overview – The Numbers That Made Twitter Excited
Result Type Lock: HALF-YEARLY RESULTS (Sep 2025)
Annualised EPS = Latest EPS × 2
Half-Yearly Performance Comparison (₹ in Crores)
Source table
Metric
Latest H1 FY26 (Sep 2025)
H1 FY25 (Sep 2024)
Previous Half
YoY %
QoQ %
Revenue
14.38
9.76
NA
47.3%
NA
EBITDA
2.93
1.98
NA
48.0%
NA
PAT
1.75
1.31
NA
33.6%
NA
EPS (₹)
2.55
13.10
NA
-80.5%
NA
Witty Commentary: Revenue is sprinting, margins are holding, but EPS looks drunk because of post-IPO equity dilution. Same profit, more shares—math doesn’t care about emotions. Annualised EPS comes to roughly ₹5.10, which puts the stock at ~33x earnings. Not cheap, not insane, but definitely priced for execution.
If growth slows, valuation will sulk. If growth continues, valuation will flex. Simple as that.
5. Valuation Discussion – Three Ways to Overthink One Stock
Method 1: P/E Based Range
Annualised EPS: ~₹5.10
Reasonable P/E range for SME pharma marketers: 25x–35x
